These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 30920046)

  • 1. Editorial: direct-acting antivirals decrease the frequency of diabetes complications in patients with chronic hepatitis C.
    Buchard B; Cacoub P; Pereira B; Abergel A
    Aliment Pharmacol Ther; 2019 Apr; 49(8):1094-1095. PubMed ID: 30920046
    [No Abstract]   [Full Text] [Related]  

  • 2. Editorial: hepatitis B reactivation in patients with chronic hepatitis C treated with direct-acting antivirals - incidence, severity of hepatitis and lessons to learn.
    Chen CH
    Aliment Pharmacol Ther; 2017 May; 45(10):1373-1374. PubMed ID: 28417500
    [No Abstract]   [Full Text] [Related]  

  • 3. Glucose Metabolism Changes in Patients with Chronic Hepatitis C Treated with Direct Acting Antivirals.
    Drazilova S; Janicko M; Skladany L; Kristian P; Oltman M; Szantova M; Krkoska D; Mazuchova E; Piesecka L; Vahalova V; Rac M; Schreter I; Virag L; Koller T; Liptakova A; Ondrasova M; Jarcuska P
    Can J Gastroenterol Hepatol; 2018; 2018():6095097. PubMed ID: 30402450
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interferon-free therapy of chronic hepatitis C with direct-acting antivirals does not change the short-term risk for de novo hepatocellular carcinoma in patients with liver cirrhosis.
    Mettke F; Schlevogt B; Deterding K; Wranke A; Smith A; Port K; Manns MP; Vogel A; Cornberg M; Wedemeyer H
    Aliment Pharmacol Ther; 2018 Feb; 47(4):516-525. PubMed ID: 29205405
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of sustained virological response by direct-acting antivirals on insulin resistance and diabetes mellitus in patients with chronic hepatitis C.
    Adinolfi LE; Rinaldi L; Marrone A; Giordano M
    Expert Rev Anti Infect Ther; 2018 Aug; 16(8):595-597. PubMed ID: 30047799
    [No Abstract]   [Full Text] [Related]  

  • 6. Early development of de novo hepatocellular carcinoma after direct-acting agent therapy: Comparison with pegylated interferon-based therapy in chronic hepatitis C patients.
    Yoo SH; Kwon JH; Nam SW; Kim HY; Kim CW; You CR; Choi SW; Cho SH; Han JY; Song DS; Chang UI; Yang JM; Lee HL; Lee SW; Han NI; Kim SH; Song MJ; Hwang S; Sung PS; Jang JW; Bae SH; Choi JY; Yoon SK
    J Viral Hepat; 2018 Oct; 25(10):1189-1196. PubMed ID: 29660199
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of histological dynamics, kidney function and diabetes in liver transplant patients after antiviral treatment with direct-acting antivirals: Therapy of HCV-recurrence.
    Teegen EM; Dürr M; Maurer MM; Eurich F; Vollbort A; Globke B; Bahra M; Blaeker H; Pratschke J; Eurich D
    Transpl Infect Dis; 2019 Feb; 21(1):e13020. PubMed ID: 30375710
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Direct-acting antiviral therapy decreases hepatocellular carcinoma recurrence rate in cirrhotic patients with chronic hepatitis C.
    Virlogeux V; Pradat P; Hartig-Lavie K; Bailly F; Maynard M; Ouziel G; Poinsot D; Lebossé F; Ecochard M; Radenne S; Benmakhlouf S; Koffi J; Lack P; Scholtes C; Uhres AC; Ducerf C; Mabrut JY; Rode A; Levrero M; Combet C; Merle P; Zoulim F
    Liver Int; 2017 Aug; 37(8):1122-1127. PubMed ID: 28423231
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunosuppressive and antiviral treatment of hepatitis C virus-associated glomerular disease: A long-term follow-up.
    Fabrizi F; Aghemo A; Lampertico P; Fraquelli M; Cresseri D; Moroni G; Passerini P; Donato FM; Messa P
    Int J Artif Organs; 2018 Jun; 41(6):306-318. PubMed ID: 29595085
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of type 2 diabetes mellitus by viral eradication in chronic hepatitis C: Myth or reality?
    Vanni E; Bugianesi E; Saracco G
    Dig Liver Dis; 2016 Feb; 48(2):105-11. PubMed ID: 26614641
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Editorial: can we afford the new direct-acting antivirals for treatment of genotype 1 hepatitis C?
    Congly SE; Lee SS
    Aliment Pharmacol Ther; 2014 Oct; 40(8):983-4. PubMed ID: 25229813
    [No Abstract]   [Full Text] [Related]  

  • 12. [Type 2 diabetes mellitus, insulin resistance and hepatocellular carcinoma in chronic hepatitis C patients.
    Lombay B; Szilágyi R; Szalay F
    Orv Hetil; 2019 Oct; 160(40):1591-1602. PubMed ID: 31565976
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chronic Hepatitis C and Direct Acting Antivirals.
    Westerhoff M; Ahn J
    Surg Pathol Clin; 2018 Jun; 11(2):287-296. PubMed ID: 29751875
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Editorial: good news to patients with thalassaemia-HCV clearance made easy with direct-acting antivirals.
    D'Ambrosio R; Lampertico P
    Aliment Pharmacol Ther; 2017 Sep; 46(6):628-629. PubMed ID: 28805329
    [No Abstract]   [Full Text] [Related]  

  • 15. IDSA/AASLD Response to Cochrane Review on Direct-Acting Antivirals for Hepatitis C.
    Powderly WG; Naggie S; Kim AY; Vargas HE; Chung RT; Lok AS
    Clin Infect Dis; 2017 Nov; 65(11):1773-1775. PubMed ID: 29020156
    [No Abstract]   [Full Text] [Related]  

  • 16. Type 2 diabetes mellitus and chronic hepatitis C: which is worse? Results of a long-term retrospective cohort study.
    Giordanino C; Ceretto S; Bo S; Smedile A; Ciancio A; Bugianesi E; Pellicano R; Fagoonee S; Versino E; Costa G; Arese D; Sacco M; Rizzetto M; Saracco G
    Dig Liver Dis; 2012 May; 44(5):406-12. PubMed ID: 22245505
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased peripheral CD4
    Langhans B; Nischalke HD; Krämer B; Hausen A; Dold L; van Heteren P; Hüneburg R; Nattermann J; Strassburg CP; Spengler U
    J Hepatol; 2017 May; 66(5):888-896. PubMed ID: 28040549
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Editorial: ribavirin continues to play a role in treatment with direct-acting antivirals for hepatitis C virus-infected patients with decompensated cirrhosis.
    Waldenström J; Lagging M
    Aliment Pharmacol Ther; 2017 Dec; 46(11-12):1115-1116. PubMed ID: 29105131
    [No Abstract]   [Full Text] [Related]  

  • 19. Therapy of chronic hepatitis C virus infection in the era of direct-acting and host-targeting antiviral agents.
    Conteduca V; Sansonno D; Russi S; Pavone F; Dammacco F
    J Infect; 2014 Jan; 68(1):1-20. PubMed ID: 24012819
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of Hepatitis C Patients in the Direct-Acting Antiviral Era.
    Teriaky A; Reau N
    Clin Liver Dis; 2015 Nov; 19(4):591-604, v. PubMed ID: 26466649
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.